Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Discover
Related topics
Recent publication of in-vivo two-photon intravital imaging study targeting mouse kidney
May 22, 2023
In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal
formation and...
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
May 5, 2023
Decision to improve the output in a lab is always taken based on knowledge and workflow needs. But final decision to...
Real-Time and Quantitative Analysis of Macrophage Phagocytosis with RTCA eSight
May 4, 2023
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Revolutionize your Flow Cytometry and Sorting workflow with Cytek Biosciences
May 3, 2023
Using full spectrum flow cytometry, Cytek systems ( RUO and CE-IVD) detect the entire fluorochrome emission, allowing...
Thermal Shift Assay using SYPRO Orange to Detect Protein Melting Temperatures
May 2, 2023
The thermal shift assay is based on temperature-induced denaturation and can be monitored using SYPRO Orange. This...
A deep learning and Monte Carlo based framework for bioluminescence imaging center Maastro
Apr 20, 2023
"In this paper,we developed a framework using deep learning for bioluminescence-based targeting for GBM animal...
Gentle sorting of microbial cells and sub-micron particles using WOLF sorter
Apr 18, 2023
While most modern applications of flow cytometry may focus on cells of eukaryotic origin, the first flow analyzers were...
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
Nov 23, 2017
Nonalcoholic fatty liver disease (NAFLD) directly affects 10–30% of the human population and is characterized by pathological alterations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and irreversible cirrhosis. NAFLD is considered a hepatic component of metabolic syndromes and is thus strongly associated with metabolic diseases such as obesity, insulin resistance, hypertension, and dyslipidemia. The prevalence of NAFLD is strongly associated with obesity and the metabolic complications of over-nutrition, which usually accompany visceral obesity. Visceral obesity is particularly associated with NAFLD. The amount of visceral fat is directly linked to the severity of liver inflammation and fibrosis in NAFLD. Human and animal studies indicate that NAFLD is strongly associated with VAT inflammation and elevated circulating inflammatory factors such as inflammatory adipokines and lipids. It is reasonable that targeting visceral adipose tissue (VAT) can contribute to the treatment and prevention of NAFLD. Accordingly, we thought it plausible that the anti-angiogenic-induced VAT loss may attenuate NAFLD during obesity.
Visualization of real-time visceral adipose tissue vasculature was performed using an FCFM imaging system (Cellvizio, Mauna Kea Technologies) with excitation and emission wavelengths of 488 and 520 nm, respectively.
Brand profile
Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
More info at:
www.cellviziolab.com/